Ian T. Clark Joins GoodRx Board of Directors
Former Genentech CEO brings over 35 years of pharmaceutical and healthcare expertise to
GoodRx
SANTA MONICA, Calif. July 10, 2024 - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us,"
"our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today
announced the election of Ian T. Clark to its Board of Directors. Mr. Clark brings to GoodRx over
35 years of experience in the pharmaceutical and healthcare industries. He formerly served as
Chief Executive Officer of Genentech, a biotechnology company, and previously held leadership
positions at Novartis, Sanofi, Ivax Pharmaceuticals and G.D. Searle. Currently, Mr. Clark is on
the board of directors of several public biopharmaceutical and biotechnology companies,
including Kyverna Therapeutics, Olema Pharmaceuticals, Takeda Pharmaceuticals, Guardant
Health and Corvus Pharmaceuticals.
“We believe Mr. Clark’s substantial experience in biopharmaceuticals and biotechnology will be
a valuable asset to GoodRx as we look to expand our work with pharma manufacturers to
deliver more affordable prices on prescriptions to consumers,” said Trevor Bezdek, GoodRx co-
founder and Chairman of the Board. “Additionally, we believe his experience leading publicly
traded companies in the healthcare industry will help further fortify our Board’s business acumen
and understanding of the complex healthcare business landscape.”
Mr. Clark has joined the Board’s Nominating and Corporate Governance Committee and will
also serve as the chairperson of the Board’s newly established Innovation Committee.
About GoodRx
GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million
consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings
and affordability options for generic and brand-name medications at more than 70,000
pharmacies nationwide, as well as comprehensive healthcare research and information. Since
2011, GoodRx has helped consumers save nearly $75 billion on the cost of their prescriptions.
GoodRx periodically posts information that may be important to investors on its investor
relations website at https://investors.goodrx.com. We intend to use our website as a means of
disclosing material nonpublic information and for complying with our disclosure obligations
under Regulation FD. Accordingly, investors and potential investors are encouraged to consult
GoodRx’s website regularly for important information, in addition to following GoodRx’s press
releases, filings with the Securities and Exchange Commission and public conference calls and
webcasts. The information contained on, or that may be accessed through, GoodRx’s website is
not incorporated by reference into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained in this press release that do
not relate to matters of historical fact should be considered forward-looking statements,
including without limitation statements regarding the anticipated contributions from Ian T. Clark
